TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05683418: A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

Sponsor: Totus Medicines · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 241 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$3,644,256

Rescue Site Savings

+$2,419,032

Unlock Full NCT05683418 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05683418 Rescue Dossier →